Sentences with phrase «primary immunodeficiency disease»

IVIG is also used to treat primary immunodeficiency disease (PIDD) and multiple sclerosis.

When Roswell Park Cancer Institute (RPCI) researchers evaluated the overall and site - specific incidence of cancer among patients registered in the United States Immune Deficiency Network (USIDNET), they found increased cancer incidence rates among patients with primary immunodeficiency diseases — and, in particular, a significant increase in lymphoma cases.

«Cancer diagnosed more often in patients with primary immunodeficiency diseases.»

Primary immunodeficiency diseases: Genomic approaches delineate heterogeneous Mendelian disorders.

Not exact matches

Childhood asthma, cystic fibrosis, chronic lung disease of infancy, pulmonary problems in children with primary immunodeficiencies

In California, state law requires that the blood be tested for about 80 diseases, including cystic fibrosis, severe combined immunodeficiency and primary congenital hypothyroidism.

(a) Growth curves of primary tumors in non-obese diabetic / severe combined immunodeficiency disease (NOD / SCID) mice injected with 5 × 105 or 5 × 104 MDA - MB 231 and MDA - MB 231 F3 cells.

By means of a non-obese diabetic / severe combined immunodeficiency disease (NOD / SCID) xenotransplant assay in combination with specific cell surface markers (CD44 + CD24 - / low), CSCs were enriched from metastatic and primary breast tumors and were shown to have the ability to reestablish tumor heterogeneity after transplantation [1].

• Patients must have adequate coagulation (international normalized ratio (INR) or prothrombin time (PT), partial thromboplastin time (PTT) ≤ 1.5 times ULN) • Adequate liver function (total bilirubin ≤ 1.5 times the ULN, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times ULN Exclusion Criteria: • Presence of active / uncontrolled central nervous system involvement • History of clinically significant cardiac disease; uncontrolled hypertension • Left ventricular ejection fraction (LVEF) < 45 % • Allogeneic stem cell transplant within 100 days before first dose of study drug • Known history of human immunodeficiency virus (HIV) infection • Chronic or active hepatitis B or C, requiring antiviral therapy • Evidence of history of bleeding disorder, dialysis, or coexisting cancer that is distinct in primary site or histology from the cancer evaluated in this study • Serious, uncontrolled infection • Unresolved chronic toxicity > grade 1 from prior therapy • Use of strong CYP3A4 inhibitors or strong inducers within 7 days prior to the start of study treatment and for the duration of the study

Studies to improve the knowledge of genetic diseases include the natural history study for MLD, advanced diagnosis and natural history of primary immunodeficiencies and immunedysregulatory disorder, and immune reconstitution after hematopoietic stem cell transplantation for genetic disorders.

Host - pathogen interface and inflammatory complications in chronic granulomatous disease, gastrointestinal complications in primary immunodeficiencies

By supporting Directive 2010 / 63 / EU, LERU wishes to call attention to the fundamental importance of the use of animals in research and the vital role it plays in understanding and providing treatment for a range of debilitating and life threatening human diseases such as cancer, primary immunodeficiencies, neuro - degenerative diseases and heart failure.

Primary Immunodeficiencies (PIDs) are a group of rare genetic diseases characterized by an altered innate and adaptive immune system, leading to increased susceptibility to infections, risk of autoimmunity and cancer.

She joined the Pillai lab as a post-doctoral research fellow in 2016 and continues to enjoy her work both treating patients with primary immunodeficiency in the clinic and studying the bridging gap between human primary immunodeficiency disorders and the development of autoimmune disease pathology in the lab.

We show signs of weak immune systems (variations of primary immunodeficiency, CVID), and «extra» allergies and sensitivities (now known to be mostly from a newly and thus still poorly recognized widespread mast cell activation disease called MCAS, ICD - 10 code coming October 2016, read «Never Bet Against Occam» by L. Afrin, MD), as well as all manner of endocrine imbalances (esp low thyroid, and often adrenal fatigue), some mitochondrial disease and / or dysfunction and all manner and forms of dysautonomia, but especially POTS in the more severe cases.

The eastern sample was recruited in the first 2 years of life from 3 pediatric clinics: 1 for children at high risk for human immunodeficiency virus disease, 1 for children with failure to thrive, and a third providing pediatric primary care.